1. Scrip

Merck’s Prevymis Set To Expand Into Renal Transplant CMV Prevention

Possible New Option

 
• By Ayisha Sharma

The major’s antiviral has hit the mark in a late-stage study of CMV disease prevention in the post kidney transplant setting, triggering plans for a US filing to expand its indication from stem cell transplant patients.  

hand reaching out to climb ladder
Prevymis Is Set To Reach New Heights With An Anticipated Label Expansion • Source: Shutterstock

Merck & Co., Inc.’s antiviral drug Prevymis (letermovir) could find a place in the prevention of cytomegalovirus (CMV) disease in renal transplant patients, following promising Phase III data showing non-inferior efficacy and more favorable safety profile than the current standard of care.

The major unveiled the study results on 22 October during the annual IDWeek meeting at Washington, DC

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D